Advanced search
Publication Cover
Ocular Immunology and Inflammation Volume 31, 2023 - Issue 10
Submit an article Journal homepage
149
Views
0
CrossRef citations to date
0
Altmetric
Original Article

Efficacy of Pegylated Interferon Alpha-2a in Uveitic Macular Edema Refractory to Biologic Agents

Mohammad Avaranda School of Medicine, Ege University, Izmir, TurkeyView further author information
, MD,
Mine Esen Barisb Department of Ophthalmology, School of Medicine, Ege University, Izmir, TurkeyORCID Iconhttps://orcid.org/0000-0003-1341-6737View further author information
, MDORCID Icon,
Leila Taherib Department of Ophthalmology, School of Medicine, Ege University, Izmir, TurkeyView further author information
, MD &
Suzan Guven Yılmazb Department of Ophthalmology, School of Medicine, Ege University, Izmir, TurkeyCorrespondence[email protected]
View further author information
, MD
Pages 1900-1905 | Received 03 May 2023, Accepted 12 Oct 2023, Published online: 02 Nov 2023

References

  • Nussenblatt RB. The natural history of uveitis. Int Ophthalmol. 1990;14(5–6):303–308. doi:10.1007/BF00163549.
  • Suttorp-Schulten MS, Rothova A. The possible impact of uveitis in blindness: a literature survey. Br J Ophthalmol. 1996;80(9):844–848. doi:10.1136/bjo.80.9.844.
  • Yalçındağ FN, Özdal PC, Özyazgan Y, Batıoğlu F, Tugal-Tutkun I, BUST Study Group. Demographic and clinical characteristics of uveitis in Turkey: the first national registry report. Ocul Immunol Inflamm. 2018;26(1):17–26. doi:10.1080/09273948.2016.1196714.
  • Yeo TK, Ho SL, Lim WK, et al. Causes of visual loss associated with uveitis in a Singapore tertiary eye center. Ocul Immunol Inflamm. 2013;21(4):264–269. doi:10.3109/09273948.2013.774424.
  • Fardeau C, Champion E, Massamba N, LeHoang P. Uveitic macular edema. Eye (Lond). 2016;30(10):1277–1292. doi:10.1038/eye.2016.115.
  • Multicenter Uveitis Steroid Treatment (MUST) Trial Research Group. Association between longlasting intravitreous fluocinolone acetonide implant vs systemic anti-inflammatory therapy and visual acuity at 7 years among patients with intermediate, posterior, or panuveitis. JAMA. 2017;317:1993–2005. doi:10.1001/jama.2017.5103.
  • Bodaghi B, Gendron G, Wechsler B, et al. Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol. 2007;91(3):335–339. doi:10.1136/bjo.2006.101550.
  • Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113:1446–1449. doi:10.1016/j.ophtha.2006.03.027.
  • Rothova A, Suttorp-van Schulten MS, Frits Treffers W, Kijlstra A. Causes and frequency of blindness in patients with intraocular inflammatory disease. Br J Ophthalmol. 1996;80:332–336. doi:10.1136/bjo.80.4.332.
  • Kawali A, Sanjay S, Mohan A, Mahendradas P, Shetty R. Topical interferon therapy in uveitic macular edema. Indian J Ophthalmol. 2022;70(12):4357–4361. doi:10.4103/ijo.IJO_1450_22.
  • Jaffe GJ, Dick AD, Brezin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med. 2016;375(10):932–943. doi:10.1056/NEJMoa1509852.
  • Mackensen F, Heinz C, Jakob E, et al. Randomized controlled study to evaluate the efficacy of adalimumab in patients with different forms of refractory uveitis. Ocul Immunol Inflamm. 2018;26(7):1015–1022. doi:10.1080/09273948.2017.1411518.
  • Lejoyeux R, Diwo E, Vallet H, et al. Infliximab and adalimumab in uveitic macular edema. Ocul Immunol Inflamm. 2018;26(7):991–996. doi:10.1080/09273948.2018.1498110.
  • Eser Ozturk H, Oray M, Tugal-Tutkun I. Tocilizumab for the treatment of behçet uveitis that failed interferon alpha and anti-tumor necrosis factor-alpha therapy. Ocul Immunol Inflamm. 2018;26(7):1005–1014. doi:10.1080/09273948.2017.1355471.
  • Plskova J, Greiner K, Forrester JV. Interferon-alpha as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol. 2007;144:55–61. doi:10.1016/j.ajo.2007.03.050.
  • Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93(7):906–913. doi:10.1136/bjo.2008.153874.
  • Wills RJ. Clinical pharmacokinetics of interferons. Clin Pharmacokinet. 1990;19(5):390–399. doi:10.2165/00003088-199019050-00003.
  • Bailon P, Palleroni A, Schaffer CA, et al. Rational design of a potent, long-lasting form of interferon: a 40 kDa branched polyethylene glycol-conjugated interferon α-2a for the treatment of hepatitis C. Bioconjug Chem. 2001;12:195–202. doi:10.1021/bc000082g.
  • Couret C, Servant M, Lebranchu P, Hamidou M, Weber M. Efficacy and safety of interferon alpha 2a and pegylated interferon alpha 2a in inflammatory macular edema. Ocul Immunol Inflamm. 2020;28(2):329–336. doi:10.1080/09273948.2019.1604001.
  • De Simone L, Gentile P, Aldigeri R, et al. Effectiveness of pegylated interferon alpha-2a in post-uveitic macular edema previously responding to non-pegylated interferon. Ocul Immunol Inflamm. 2023;1–5. doi:10.1080/09273948.2023.2195494.
  • Agrawal R, Agarwal A, Jabs DA, et al. Standardization of nomenclature for ocular tuberculosis–results of collaborative Ocular Tuberculosis Study (COTS) workshop. Ocul Immunol Inflamm. 2020;28(sup1):74–84. doi:10.1080/09273948.2019.1653933.
  • Radosavljevic A, Agarwal M, Bodaghi B, Smith JR, Zierhut M. Medical therapy of uveitic macular edema: biologic agents. Ocul Immunol Inflamm. 2020;28(8):1239–1250. doi:10.1080/09273948.2019.1709648.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.